Financial Performance - Consolidated - Q4 Net Sales increased by 39% to $378.7 million compared to $273.2 million in FY24[13] - Q4 Adjusted EBITDA increased by 49% to $50.0 million compared to $33.4 million in FY24[13] - Full Year Net Sales increased by 27% to $1,296.2 million compared to $1,017.7 million in FY24[16] - Full Year Adjusted EBITDA increased by 65% to $183.7 million compared to $111.2 million in FY24[16] Financial Performance - Animal Health - Q4 Animal Health Net Sales increased by 53% to $292.5 million[11,19] - Q4 Legacy Animal Health Net Sales increased by 3% to $197.9 million[11,19] - Full Year Animal Health Net Sales increased by 36% to $962.8 million[11,22] - Full Year Legacy Animal Health Net Sales increased by 7% to $754.6 million[11,22] Financial Guidance - Fiscal Year 2026 - The company projects Net Sales between $1.425 billion and $1.475 billion[12] - The company projects Adjusted EBITDA between $225 million and $235 million[12]

Core Insights - Phibro Animal Health (PAHC) shares have increased by 76.4% over the past year, significantly outperforming the industry growth of 4.9% and the S&P 500's 16% gain [1][8] - The company is currently ranked 2 (Buy) by Zacks, indicating strong fundamentals and growth potential [1] Company Overview - Phibro, based in New Jersey, offers a wide range of products for food animals, including poultry, swine, beef, dairy cattle, and aquaculture, as well as ingredients for personal care and industrial sectors [2] - The company is focusing on expanding its product offerings in the companion animal sector [2] Growth Drivers - The surge in PAHC's share price is attributed to a strong sales recovery in its Mineral Nutrition and Performance Products segments, with Mineral Nutrition growing by 4% year over year and Performance Products increasing by 28% year over year [3] - The recent acquisition of medicated feed additive products and certain water-soluble products from Zoetis Inc. has expanded Phibro's Animal Health product portfolio [3] International Market Contribution - Approximately 40% of Phibro's total revenues come from international markets, including high-growth regions such as Brazil, China, India, and Southeast Asia [4] Financial Health - Phibro has a solid financial position, with a low short-term payable debt of $16 million compared to total cash and short-term investments of $70.4 million [5] - The company reported an operating profit of $33.4 million for the fiscal third quarter, reflecting a 67.8% year-over-year increase and an expansion of the operating margin by 204 basis points [5] Earnings Estimates - Phibro's earnings per share (EPS) are projected to increase by 71.4% to $2.04 for fiscal 2025 and by 12.7% to $2.30 for fiscal 2026 [9] - Revenues are expected to grow by 25.7% to $1.28 billion in fiscal 2025 and reach $1.41 billion in fiscal 2026, indicating a 10.1% increase [9]

Core Points - The board of directors of Virbac has approved the compensation terms for Paul Martingell as CEO, which will be submitted for shareholder approval [1] Fixed Compensation - Paul Martingell's gross annual fixed compensation is set at €600,000, including other remuneration related to his mandates within the Virbac group [2] - For 2025, the fixed compensation will be prorated based on his effective presence from September 1, 2025, to December 31, 2025 [2] Short-term Variable Compensation - The short-term variable compensation will be determined based on the achievement of objectives, measured by the board during the first quarter of the following fiscal year after the approval of annual financial statements [3] Long-term Incentive (LTI) Compensation - Paul Martingell will receive 1,000 performance shares under the performance share plan established on March 12, 2025 [4] - Future performance share plans may award him shares equivalent to his gross annual fixed compensation, capped at 1,500 performance shares [5] Exceptional Compensation: Onboarding Bonus - To compensate for lost benefits from his previous role, Martingell will receive 2,000 performance shares after two years, contingent on achieving an Ebit adjusted greater than 10% [6] - An additional 1,000 performance shares will be granted after three years under the same Ebit condition [7] - A welcome bonus of €500,000 gross in cash will be paid in two installments [9] Other Compensation Elements and Benefits - Martingell will benefit from French social security, healthcare, and retirement schemes [12] - He will have private unemployment insurance fully covered by the company [13] - A company car will be provided as a benefit in kind [14] - Relocation costs to the Nice region will be covered, including a furnished rental for four months, capped at €2,000 per month [15] Non-compete Agreement and Indemnity - Martingell will be subject to a non-compete clause for 18 months post-cessation of his role, with an indemnity of 80% of his gross monthly fixed compensation during this period, capped at €600,000 [16][18][19]

Financial Data and Key Metrics Changes - The company reported revenues of $298,000, representing a 141% increase compared to the same quarter last year [6][4] - Gross profit totaled $187,000, which is 63% of revenues, marking a 69% increase from $111,000 in the same quarter last year [7] - Operating loss decreased by 10% to $1,800,000 compared to the same quarter a year ago [8] - Net loss available to common stockholders was $2,300,000, or a negative loss of $0.09 per share, which is a 15% improvement from the previous year's net loss of $2,000,000 [8] - Available cash increased to $3,300,000 from $220,000 as of March 31, 2025 [9] - Total liabilities decreased by 39% to $1,200,000 during the quarter [9] Business Line Data and Key Metrics Changes - The U.S. National distributor network increased sales by 192% year-over-year, contributing $198,000 or 67% of total revenue [4][6] - The introduction of the new Precise PRP product alongside Spring contributed to the revenue increase [6] Market Data and Key Metrics Changes - The Mexican veterinary health care market is projected to grow at a compounded annual growth rate of 11%, reaching $2.4 billion by February 2031 [3] - The U.S. animal health market is expected to double to $11.3 billion by February 2030, providing significant growth opportunities [24] Company Strategy and Development Direction - The company is focused on expanding the adoption of its flagship product, Spring, and increasing awareness of Precise PRP for treating osteoarthritis in animals [12] - Strategic partnerships have been formed, including collaborations with Commonwealth Markets and Piezo BioMembrane, to enhance product offerings and market reach [20][22] - The company is integrating AI technology with its veterinary products to create a global pet care ecosystem [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for fiscal 2026 and beyond [24] - The company believes it is well-positioned to accelerate growth and expand into high-growth markets [24] Other Important Information - The company has recently qualified to trade on the OTCQX best market, enhancing visibility and liquidity for investors [11] - The commercialization of Spring and Precise PRP has received favorable feedback from veterinarians regarding their effectiveness [14] Q&A Session Summary - No questions were raised during the Q&A session, leading to the conclusion of the call [29][33]

Core Insights - ImmuCell Corporation reported significant improvements in financial performance for the second quarter and six-month period ended June 30, 2025, including a net income of approximately $502,000 for the quarter and $1.9 million for the six months, contrasting with net losses in the same periods of 2024 [4][8]. Product Sales Highlights - Product sales for the second quarter of 2025 increased by 18% to approximately $6.4 million compared to the same quarter in 2024 [7]. - For the six-month period ended June 30, 2025, product sales rose by 14% to approximately $14.5 million compared to the same period in 2024 [7]. - Over the twelve-month period ended June 30, 2025, product sales increased by 22% to approximately $28.3 million compared to the previous year [7]. Financial Performance - Gross margin improved to 44% for the three-month period and 43% for the six-month period ended June 30, 2025, compared to 22% and 28% respectively in 2024 [8]. - Adjusted EBITDA improved to approximately $1.4 million, $3.7 million, and $5.3 million for the three-month, six-month, and twelve-month periods ended June 30, 2025, respectively [8][16]. Balance Sheet Strength - Cash and cash equivalents increased to approximately $6.0 million as of June 30, 2025, up from $3.8 million at the end of 2024 [8][14]. - Net working capital rose to approximately $12.7 million as of June 30, 2025, compared to $10.6 million at the end of 2024 [8][14]. - Stockholders' equity increased to approximately $29.9 million as of June 30, 2025, from $27.5 million at the end of 2024 [9]. Strategic Initiatives - The company has eliminated the backlog of orders as of June 30, 2025, and is building inventory to meet customer demand for the peak selling season [4]. - ImmuCell has initiated Investigational Product use for Re-Tain to collect market feedback on product performance during the second half of 2025 and into early 2026 [4].

ImmuCell Corporation Investor Presentation August 2025 (Nasdaq: ICCC) 2 Table of Contents | 1) | Company Overview and Strategic Opportunity..…….……..…………………………………………………….….… 4-27 | | --- | --- | | 2) | Testimonials………………………………………………………………….……..…….…………………………………….……….…28-32 | | 3) | Financial Review(1).………………..….……..……………………………..……………………………………………..… 33-39 | | 4) | Other Information..……………...………...………………………………………….……………………………...……….…….40-52 | (1)Detailed financial reports, summary press releases and conference ...

Core Viewpoint - ImmuCell Corporation has successfully refinanced a portion of its bank debt, which is expected to improve its financial position and operational flexibility [1][2]. Financial Summary - The company secured a new loan from Maine Community Bank (MCB) amounting to $2,327,119 at a fixed interest rate of 6.5% per annum [2]. - The proceeds were utilized to pay off an existing loan from MCB with a balance of $1,525,852 at 7% interest and another loan from the Finance Authority of Maine (FAME) with a balance of $768,209 at 8% interest [2]. - The paid-off loans had balloon principal payments totaling approximately $1,946,000 due in the third quarter of 2026 [2]. - The new loan features a five-year amortization schedule, concluding in the third quarter of 2030 [2]. Management Commentary - The President and CEO of ImmuCell expressed appreciation for the ongoing relationship with MCB and acknowledged the support from FAME, particularly during mid-2023 [3]. - By paying off the FAME loan early, the company aims to free up funds for other uses within the State of Maine [3]. Upcoming Events - ImmuCell plans to host a conference call on August 15, 2025, to discuss the unaudited financial results for the quarter ended June 30, 2025 [3]. Company Overview - ImmuCell Corporation focuses on developing and marketing products that enhance the health and productivity of dairy and beef cattle [4]. - The company manufactures First Defense, which provides Immediate Immunity™ to newborn calves, and is developing Re-Tain, a treatment for subclinical mastitis in dairy cows [4].

Core Viewpoint - The healthcare sector is currently undervalued, presenting opportunities for investors to acquire quality stocks at discounted prices [1][2]. Group 1: Zoetis - Zoetis operates in the animal health industry, providing a wide range of drugs and healthcare products for companion animals and livestock, with a portfolio of approximately 300 product lines [3][4]. - The animal health market is projected to grow from $48 billion in 2023 to between $75 billion and $85 billion by 2033, with Zoetis historically outpacing industry growth [4]. - Zoetis has a P/E ratio of 25, its lowest ever, and is expected to grow earnings by 9% to 10% annually over the next three to five years, making it an attractive long-term investment [5]. Group 2: Johnson & Johnson - Johnson & Johnson is a major player in pharmaceuticals and medical devices, having spun off its consumer products segment to focus on faster-growing areas [6][7]. - The company has a strong dividend history, having paid and raised its dividend for 63 consecutive years, with a current yield of 3% [7][8]. - The stock trades at a P/E ratio of 18, with expected annualized earnings growth of just over 7% in the coming years [8]. Group 3: Zimmer Biomet - Zimmer Biomet specializes in products for joint replacement, dental implants, and surgical robotics, addressing the needs of an aging population [9][10]. - The company has a low dividend payout ratio, currently at 12% of estimated 2025 earnings, indicating potential for significant dividend growth [11]. - Zimmer Biomet trades at 11 times 2025 earnings estimates, with expected earnings growth of 5% to 6% annually over the next three to five years [12].

Company Performance - Over the past decade, an investment in Zoetis (ZTS) would have grown by 227%, averaging an annual return of 12.6% [2] - However, the S&P 500 outperformed Zoetis with an average annual gain of 12.7% during the same period [2] - In shorter time frames, Zoetis shares have underperformed, with annual average declines of 18.7%, 4.25%, and 0.43% over the past one, three, and five years respectively [3] Growth Potential - Zoetis has significant growth potential, having been spun off from Pfizer in 2013 and now leading in market share across various animal health segments [4] - The company has made strategic acquisitions to enhance its market position [4] Resilience and Dividends - The company is considered somewhat recession-proof, as animal health care is essential for both livestock and pets [6] - Zoetis offers a dividend yield of 1.3%, with total annual payouts increasing from $0.50 in 2018 to $1.93 per share recently [7] - The current forward-looking price-to-earnings (P/E) ratio of 24 is below the five-year average of 32, suggesting shares may be undervalued [7]

a first on CNBC interview is Elanco CEO Jeff Simmons. Jeff, I just want to talk about this because I have a personal interest as an owner of two dogs. And I want to say now, six fish.At this point, we have animals throughout our house. Our kids love them. What exactly is driving the demand for animal health products.To the point that we've seen your stock jump the way that it did. >> Tom, great to be with you this morning. And it's exactly that.And that is that the personalization of that pet in the home, t ...